Articles and news
UK-US pharma pricing arrangement
MFN isn’t slowing down. It’s getting operational
The UK isn’t rejecting medicines
Cancer waiting times aren’t just a performance metric
Broad but shallow markets in primary care
Uptake of NICE Technology Appraisals
What’s going on at NICE?
The Access Paradox: When NICE Meets NHS Reality
The 90‑day clock is not your launch clock
Rethinking the “erosion of in‑house capability” risk
From NICE approval to real‑world access
Why Pharma Must Redesign Its Engagement
Stop haggling over drug price. Start buying productivity.
Cancer innovation meets NHS reality (2025)
The new ICB map is not less local. It is differently local
MFN and the small Pharma squeeze
Faster uptake for drugs in an established class
Are drugs quietly deciding who gets seen in the NHS?
Reimbursement ≠ patient access
NICE’s ICER threshold change & UK launch market
Is the UK about to stop getting new drugs?
MFN is quietly reshaping how you launch globally
